Magnetic resonance guided high-intensity focused ultrasound mediated hyperthermia improves the intratumoral distribution of temperature-sensitive liposomal doxorubicin

Investigative Radiology

Volumn 48, Issue 6, 2013, Pages 395-405

  De Smet, Mariska ^a   Hijnen, Nicole M ^a   Langereis, Sander ^b   Elevelt, Aaldert ^b   Heijman, Edwin ^b   Dubois, Ludwig ^c   Lambin, Philippe ^c   Grüll, Holger ^a,b  

^a EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

^b PHILIPS RESEARCH LABORATORIES   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

doxorubicin; highintensity focused ultrasound; hyperthermia; intratumoral distribution; temperature sensitive liposomes

Indexed keywords

DOXORUBICIN; GADOTERIDOL; LIPOSOME IN 111;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG RELEASE; ENCAPSULATION; FEMALE; FLUORESCENCE MICROSCOPY; HIGH INTENSITY FOCUSED ULTRASOUND; HYPERTHERMIC THERAPY; IMAGING SYSTEM; ISOTOPE LABELING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; RAT; RHABDOMYOSARCOMA; TEMPERATURE SENSITIVITY;

EID: 84877581293     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e3182806940     Document Type: Article

References (56)

1. Cline HE, Hynynen K, Hardy CJ, et al. MR temperature mapping of focused ultrasound surgery. Magn Reson Med. 1994;31:628-636.
2. Ishihara Y, Calderon A, Watanabe H, et al. A precise and fast temperature mapping using water proton chemical shift. Magn Reson Med. 1995;34: 814-823.
3. Hynynen K, Darkazanli A, Unger E, et al. MRI-guided noninvasive ultrasound surgery. Med Phys. 1993;20:107-115.
4. Partanen A, Yarmolenko PS, Viitala A, et al. Mild hyperthermia with magnetic resonanceYguided high-intensity focused ultrasound for applications in drug delivery. Int J Hyperthermia. 2012;28:320-336.
5. Enholm JK, Kohler MO, Quesson B, et al. Improved volumetric MR-HIFU ablation by robust binary feedback control. IEEE Trans Biomed Eng. 2010;57:103-113.
6. Staruch R, Chopra R, Hynynen K. Localised drug release using MRI-controlled focused ultrasound hyperthermia. Int J Hyperthermia. 2011;27:156-171.
7. Issels RD, Lindner LH, Verweij J, et al. Neo-adjuvant chemotherapy alone with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol. 2010;11:561-570.
8. van der Zee J. Heating the patient: a promising approach? Ann Oncol. 2002;13:1173-1184.
9. Franckena M, Stalpers LJA, Koper PCM, et al. Long-term improvement in treatment outcome after radiotherapy and hyperthermia in locoregionally advanced cervix cancer: an update of the Dutch Deep Hyperthermia Trial. Int J Radiat Oncol Biol Phys. 2008;70:1176-1182.
10. Skitzki JJ, Repasky EA, Evans SS. Hyperthermia as an immunotherapy strategy for cancer. Curr Opin Investig Drugs. 2009;10:550-558.
11. Roti Roti JL. Cellular responses to hyperthermia (40-46 degrees C): cell killing and molecular events. Int J Hyperthermia. 2008;24:3-15.
12. Koning GA, Eggermont AMM, Lindner LH, et al. Hyperthermia and thermosensitive liposomes for improved delivery of chemotherapeutic drugs to solid tumors. Pharm Res. 2010;27:1750-1754.
13. Kong G, Braun RD, Dewhirst MW. Characterisation of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Res. 2001;61:3027-3032.
14. Gaber MH, Wu NZ, Hong K, et al. Thermosensitive liposomes: extravasation and release of contents in tumor microvascular networks. Int J Radiat Oncol Biol Phys. 1996;36:1177-1187.
15. Landon CD, Park J, Needham D, et al. Nanoscale drug delivery and hyperthermia: the materials design and preclinical and clinical testing of low temperaturesensitive liposomes used in combination with mild hyperthermia in the treatment of local cancer. Open Nanomed J. 2011;3:38-64.
16. Krawczyk PM, Eppink B, Essers J, et al. Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition. Proc Natl Acad Sci. 2011;108: 9851-9856.
17. Tunggal JK, Cowan DSM, Shaikh H, et al. Penetration of anticancer drugs through solid tissue: a factor that limits the effectiveness of chemotherapy for solid tumors. Clin Cancer Res. 1999;5:1583-1586.
18. Tannock IF, Lee CM, Tunggal JK, et al. Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res. 2002;8:878-884.
19. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer. 2006;6:583-592.
20. Primeau AJ, Rendon A, Hedley D, et al. The distribution of the anticancer drug doxorubicin in relation to blood vessels in solid tumors. Cancer Ther. 2005;11:8782-8788.
21. Kong G, Dewhirst MW. Hyperthermia and liposomes. Int J Hyperthermia. 1999;15:345-370.
22. Yatvin MB,Weinstein JN, Dennis WH, et al. Design of liposomes for enhanced local release of drugs by hyperthermia. Science. 1978;202:1290-1293.
23. Weinstein JN, Magin RL, Yatvin MB, et al. Liposomes and local hyperthermiaV selective delivery of methotrexate to heated tumors. Science. 1979;204:188-191.
24. Kong G, Anyarambhatla G, Petros WP, et al. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res. 2000;60:6950-6957.
25. Needham D, Anyarambhatla G, Kong G, et al. A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res. 2000;60:1197-1201.
26. Ranjan A, Jacobs GC, Woods DL, et al. Image-guided drug delivery with magnetic resonance guided high intensity focused ultrasound and temperature sensitive liposomes in a rabbit Vx2 tumor model. J Control Release. 2012;158: 487-494.
27. Aoki H, Kakinuma K, Morita K, et al. Therapeutic efficacy of targeting chemotherapy using local hyperthermia and thermosensitive liposome: evaluation of drug distribution in a rat glioma model. Int J Hyperthermia. 2004;20: 595-605.
28. Dromi S, Frenkel V, Luk A, et al. Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clin Cancer Res. 2007;13:2722-2727.
29. Gasselhuber A, Dreher MR, Rattay F, et al. Comparison of conventional chemotherapy, stealth liposomes and temperature-sensitive liposomes in a mathematical model. PLoS One. 2012;7:e47453.
30. Laginha KM, Verwoert S, Charrois GJR, et al. Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin Cancer Res. 2005;11:6944-6949.
31. Seynhaeve ALB, Hoving S, Schipper D, et al. Tumor necrosis factor alpha mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response. Cancer Res. 2007;67:9455-9462.
32. Staruch RM, Ganguly M, Tannock IF, et al. Enhanced drug delivery in rabbit VX2 tumours using thermosensitive liposomes and MRI-controlled focused ultrasound hyperthermia. Int J Hyperthermia. 2012;28:776-787.
33. Ponce AM, Viglianti BL, Yu D, et al. Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects. J Natl Cancer Inst. 2007;99:53-63.
34. Viglianti BL, Ponce AM, Michelich CR, et al. Chemodosimetry of in vivo tumor liposomal drug concentration using MRI. Magn Reson Med. 2006; 56:1011-1018.
35. Negussie AH, Yarmolenko PS, Partanen A, et al. Formulation and characterisation of magnetic resonance imageable thermally sensitive liposomes for use with magnetic resonanceYguided high intensity focused ultrasound. Int J Hyperthermia. 2011;27:140-155.
36. de Smet M, Heijman E, Langereis S, et al. Magnetic resonance imaging of high intensity focused ultrasound mediated drug delivery from temperaturesensitive liposomes: an in vivo proof-of-concept study. J Control Release. 2011;150:102-110.
37. Tagami T, Foltz WD, Ernsting MJ, et al. MRI monitoring of intratumoral drug delivery and prediction of the therapeutic effect with a multifunctional thermosensitive liposome. Biomaterials. 2011;32:6570-6578.
38. de Smet M, Langereis S, van den Bosch S, et al. Temperature-sensitive liposomes for doxorubicin delivery under MRI guidance. J Control Release. 2010;143:120-127.
39. Hak S, Sanders HM, Agrawal P, et al. A high relaxivity Gd(III)DOTADSPEYbased liposomal contrast agent for magnetic resonance imaging. Eur J Pharm Biopharm. 2009;72:397-404.
40. Rouser G, Fleische S, Yamamoto A. 2 Dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids. 1970;5:494.
41. Dubois LJ, Lieuwes NG, Janssen MH, et al. Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging. Proc Natl Acad Sci U S A. 2011;108:14620-14625.
42. Hijnen NM, Heijman E, Kohler MO, et al. Tumour hyperthermia and ablation in rats using a clinical MR-HIFU system equipped with a dedicated small animal set-up. Int J Hyperthermia. 2012;28:141-155.
43. Look DC, Locker DR. Time saving in measurement of NMR and EPR relaxation times. Rev Sci Instrum. 1970;41:250-251.
44. Shin W, Gu H, Yang Y. Fast high-resolution T1 mapping using inversionrecovery Look-Locker echo-planar imaging at steady state: optimization for accuracy and reliability. Magn Reson Med. 2009;61:899-906.
45. Manzoor AA, Lindner LH, Landon CD, et al. Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors. Cancer Res. 2012;72:5566-5575.
46. Forssen EA, Male-Brune R, Adler-Moore JP, et al. Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue. Cancer Res. 1996;56:2066-2075.
47. Uster PS, Working PK, Vaage J. Pegylated liposomal doxorubicin (Doxil\, Caelyx\), distribution in tumour models observed with confocal laser scanning microscopy. Int J Pharm. 1998;162:77-86.
48. Judson I, Radford JA, Harris M, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL\/CAELYX\) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2001;37:870-877.
49. Harris L, Batist G, Belt R, et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer. 2002;94:25-36.
50. O'Brien MER, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYXi/Doxil\) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15:440-449.
51. Working PK, Newman MS, Huang SK, et al. Pharmacokinetics, biodistribution and therapeutic efficacy of doxorubicin encapsulated in stealth\ liposomes (Doxil\). J Liposome Res. 1994;4:667-687.
52. Harashima H, Iida S, Urakami Y, et al. Optimization of antitumor effect of liposomally encapsulated doxorubicin based on simulations by pharmacokinetic/pharmacodynamic modeling. J Control Release. 1999;61:93-106.
53. Eakins MN, Eaton SM, Fisco RA, et al. Physicochemical properties, pharmacokinetics and biodistribution of Gadoteridol injection in rats and dogs. Acad Radiol. 1995;2:584-591.
54. Koning GA, Eggermont AM, Lindner LH, et al. Hyperthermia and thermosensitive liposomes for improved delivery of chemotherapeutic drugs to solid tumors. Pharm Res. 2010;27:1750-1754.
55. Grull H, Langereis S. Hyperthermia-triggered drug delivery from temperaturesensitive liposomes using MRI-guided high intensity focused ultrasound. J Control Release. 2012;161:317-327.
56. Dromi S, Frenkel V, Luk A, et al. Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clin Cancer Res. 2007;13:2722-2727.